|
1
|
Davar D, Beumer JH, Hamieh L and Tawbi H:
Role of PARP inhibitors in cancer biology and therapy. Curr Med
Chem. 19:3907–3921. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirai T, Shirai H, Fujimori H, Okayasu R,
Sasai K and Masutani M: Radiosensitization effect of
poly(ADP-ribose) polymerase inhibition in cells exposed to low and
high liner energy transfer radiation. Cancer Sci. 103:1045–1050.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Michels J, Vitale I, Senovilla L, et al:
Synergistic interaction between cisplatin and PARP inhibitors in
non-small cell lung cancer. Cell Cycle. 12:877–883. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Soto JA, Wang X, Tominaga Y, et al: The
inhibition and treatment of breast cancer with poly (ADP-ribose)
polymerase (PARP-1) inhibitors. Int J Biol Sci. 2:179–185. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bryant HE, Schultz N, Thomas HD, et al:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farmer H, McCabe N, Lord CJ, et al:
Targeting the DNA repair defect in BRCA mutant cells as a
therapeutic strategy. Nature. 434:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murphy CG and Moynahan ME: BRCA gene
structure and function in tumor suppression: a repair-centric
perspective. Cancer J. 16:39–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hilton JF, Hadfield MJ, Tran MT and
Shapiro GI: Poly(ADP-ribose) polymerase inhibitors as cancer
therapy. Front Biosci. 1:1392–1406. 2013. View Article : Google Scholar
|
|
9
|
Gupta SC, Sung B, Prasad S, Webb LJ and
Aggarwal BB: Cancer drug discovery by repurposing: teaching new
tricks to old dogs. Trends Pharmacol Sci. 34:508–157. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dueñas-González A, García-López P, Herrera
LA, Medina-Franco JL, González-Fierro A and Candelaria M: The
prince and the pauper. A tale of anticancer targeted agents. Mol
Cancer. 7:822008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Surjana D, Halliday GM and Damian DL: Role
of nicotinamide in DNA damage, mutagenesis, and DNA repair. J
Nucleic Acids. 2010:pii: 157591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Knip M, Douek IF, Moore WP, et al:
European Nicotinamide Diabetes Intervention Trial Group Safety of
high-dose nicotinamide: a review. Diabetologia. 43:1337–1345. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Virag L and Szabo C: The therapeutic
potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev.
54:375–342. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen G and Zeller WJ: Reversal of acquired
cisplatin resistance by nicotinamide in vitro and in vivo. Cancer
Chemother Pharmacol. 3:157–162. 1993. View Article : Google Scholar
|
|
15
|
Kaanders JH, Bussink J and Van der Kogel
AJ: ARCON: a novel biology-based approach in radiotherapy. Lancet
Oncol. 3:728–737. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Janssens GO, Rademakers SE, Terhaard CH,
et al: Accelerated radiotherapy with carbogen and nicotinamide for
laryngeal cancer: results of a phase III randomized trial. J Clin
Oncol. 30:1777–1783. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bernier J, Denekamp J, Rojas A, et al:
ARCON: accelerated radiotherapy with carbogen and nicotinamide in
head and neck squamous cell carcinomas. The experience of the
Co-operative group of radiotherapy of the european organization for
research and treatment of cancer (EORTC). Radiother Oncol.
55:111–119. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bernier J, Denekamp J, Rojas A, et al:
ARCON: accelerated radiotherapy with carbogen and nicotinamide in
non-small cell lung cancer: a phase I/II study by the EORTC.
Radiother Oncol. 52:149–56. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Handfield-Jones S, Jones SK and Peachey
RD: Nicotinamide treatment in diabetes. Br J Dermatol. 116:2771987.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niren NM: Pharmacologic doses of
nicotinamide in the treatment of inflammatory skin conditions: a
review. Cutis. 77(1 Suppl): 11–16. 2006.PubMed/NCBI
|
|
21
|
Kolb H and Burkart V: Nicotinamide in type
1 diabetes. Mechanism of action revisited. Diabetes Care. 22(Suppl
2): B16–B20. 1999.PubMed/NCBI
|
|
22
|
Vallely JF, Lovegrove TD and Hobbs GE:
Nicotinic acid and nicotinamide in the treatment of chronic
schizophrenia. Can Psychiatr Assoc J. 16:433–435. 1971.PubMed/NCBI
|
|
23
|
Jung-Hynes B, Nihal M, Zhong W and Ahmad
N: Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A
target for prostate cancer management via its inhibition? J Biol
Chem. 284:3823–3832. 2009. View Article : Google Scholar :
|
|
24
|
Audrito V, Vaisitti T, Rossi D, et al:
Nicotinamide blocks proliferation and induces apoptosis of chronic
lymphocytic leukemia cells through activation of the
p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res.
71:4473–4483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Evers B, Drost R, Schut E, et al:
Selective inhibition of BRCA2-deficient mammary tumor cell growth
by AZD2281 and cisplatin. Clin Cancer Res. 14:3916–3925. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Löser DA, Shibata A, Shibata AK, Woodbine
LJ, Jeggo PA and Chalmers AJ: Sensitization to radiation and
alkylating agents by inhibitors of poly(ADP-ribose) polymerase is
enhanced in cells deficient in DNA double-strand break repair. Mol
Cancer Ther. 9:1775–1787. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang T, Cui H, Ma N and Jiang Y:
Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated
with the viability of cancer cells exposed to antitumor agents and
apoptosis. Oncol Lett. 6:600–604. 2013.PubMed/NCBI
|
|
28
|
Gong DJ, Zhang JM, Yu M, Zhuang B and Guo
QQ: Inhibition of SIRT1 combined with gemcitabine therapy for
pancreatic carcinoma. Clin Interv Aging. 8:889–897. 2013.PubMed/NCBI
|
|
29
|
Dragovic J, Kim SH, Brown SL and Kim JH:
Nicotinamide pharmacokinetics in patients. Radiother Oncol.
36:225–228. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bernier J, Stratford MR, Denekamp J, et
al: Pharmacokinetics of nicotinamide in cancer patients treated
with accelerated radiotherapy: the experience of the Co-operative
Group of Radiotherapy of the European Organization for Research and
Treatment of Cancer. Radiother Oncol. 48:123–133. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Horsman MR, Hoyer M, Honess DJ, Dennis IF
and Overgaard J: Nicotinamide pharmacokinetics in humans and mice:
a comparative assessment and the implications for radiotherapy.
Radiother Oncol. 27:131–139. 1993. View Article : Google Scholar : PubMed/NCBI
|
